Company Enlivex Therapeutics Ltd.

Equities

ENLV

IL0011319527

Biotechnology & Medical Research

Analysts' Consensus

Business Summary

Managers

Members of the board

Share class

Shareholders

Company contact information

Sector

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-15 pm EDT			5-day change	1st Jan Change
1.42 ^USD	-2.07%		-8.39%	-47.41%

Apr. 22	Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	MT
Apr. 22	Enlivex Therapeutics Ltd. Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra? in Patients with Knee Osteoarthritis	CI

Enlivex Therapeutics Ltd is an Israel-based clinical stage macrophage reprogramming immunotherapy company developing Allocetra, off-the-shelf cell therapy designed to reprogram macrophages into their homeostatic state. AllocetraTM is a therapy designed to reprogram macrophages into their homeostatic state. Diseases such as solid cancers, sepsis, COVID-19 and many others reprogram macrophages out of their homeostatic state. These non-homeostatic macrophages contribute significantly to the severity of the respective diseases. By restoring macrophage homeostasis, AllocetraTM has the potential to provide immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as unmet medical needs, as a stand-alone therapy or in combination with therapeutic agents.

Managers	Title	Age	Since
Oren Hershkovitz CEO	Chief Executive Officer	47	19-11-15
Dror Mevorach FOU	Founder	68	08-12-31
Shachar Shlosberger DFI	Director of Finance/CFO	47	15-12-31
Veronique Amor-Baroukh COO	Chief Operating Officer	-	-
Sigal Arad HRO	Human Resources Officer	-	-
Iris Tavor LAW	General Counsel	-	-
Einat Galamidi PRN	Corporate Officer/Principal	-	22-02-21
Oren Elmaliah AUD	Comptroller/Controller/Auditor	40	17-01-31

Members of the board	Title	Age	Since
Shai Novik CHM	Chairman	58	13-12-31
Avri Havron BRD	Director/Board Member	76	13-12-31
Brian Schwartz BRD	Director/Board Member	52	20-11-30
Roger Pomerantz BRD	Director/Board Member	67	22-05-22
Gili Hart BRD	Director/Board Member	49	13-12-31
Andrew Singer BRD	Director/Board Member	53	23-04-16

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	18,811,781	15,198,104 ( 80.79 %)	0	80.79 %

Name	Equities	%	Valuation
Kip Global Pharma Ecosystem Private Equity Fund 7.628 %	1,417,950	7.628 %	2 M $
Hadasit Bio-Holdings Ltd. /Private Equity/ 5.412 %	1,006,007	5.412 %	1 M $
Shai Novik 4.055 %	753,764	4.055 %	1 M $
Dror Mevorach 1.262 %	234,657	1.262 %	340 253 $
Avri Havron 0.9568 %	177,852	0.9568 %	257 885 $
Renaissance Technologies LLC 0.3760 %	69,889	0.3760 %	101 339 $
Susquehanna Securities LLC 0.3655 %	67,943	0.3655 %	98 517 $
KSM Mutual Funds Ltd. 0.2516 %	46,766	0.2516 %	67 811 $
IBI Mutual Funds Management (1978) Ltd. 0.2246 %	41,750	0.2246 %	60 538 $
Migdal Mutual Funds Ltd. 0.1555 %	28,899	0.1555 %	41 904 $

Enlivex Therapeutics Ltd.

14 Einstein Street

7403618, Ness Ziona

http://www.enlivex.com

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

1.42 USD

Average target price

7 USD

Spread / Average Target

+392.96%

Consensus

Estimates Revisions

Company calendar

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
ENLIVEX THERAPEUTICS LTD.	-47.41%	26.71M
VERTEX PHARMACEUTICALS INCORPORATED	+7.52%	113B
REGENERON PHARMACEUTICALS, INC.	+11.38%	106B
BIONTECH SE	-12.64%	22.22B
ARGENX SE	+0.44%	22.27B
GENMAB A/S	-4.18%	19.43B
WUXI APPTEC CO., LTD.	-37.85%	17.87B
BEIGENE, LTD.	-8.58%	17.24B
SAREPTA THERAPEUTICS, INC.	+37.41%	12.52B
LEGEND BIOTECH CORPORATION	-23.95%	8.34B

Bio Therapeutic Drugs